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Abstract
Background: Heart rate (HR) is an emerging risk factor in coronary artery disease (CAD). However, there is little
contemporary data regarding HR and the use of HR-lowering medications, particularly beta-blockers, among patients with
stable CAD in routine clinical practice. The goal of the present analysis was to describe HR in such patients, overall and in
relation to beta-blocker use, and to describe the determinants of HR.
Methods and Findings: CLARIFY is an international, prospective, observational, longitudinal registry of outpatients with
stable CAD, defined as prior myocardial infarction or revascularization procedure, evidence of coronary stenosis of .50%, or
chest pain associated with proven myocardial ischemia. A total of 33,438 patients from 45 countries in Europe, the Americas,
Africa, Middle East, and Asia/Pacific were enrolled between November 2009 and July 2010. Most of the 33,177 patients
included in this analysis were men (77.5%). Mean (SD) age was 64.2 (10.5) years, HR by pulse was 68.3 (10.6) bpm, and by
electrocardiogram was 67.2 (11.4) bpm. Overall, 44.0% had HR$70 bpm. Beta-blockers were used in 75.1% of patients and
another 14.4% had intolerance or contraindications to beta-blocker therapy. Among 24,910 patients on beta-blockers,
41.1% had HR$70 bpm. HR$70 bpm was independently associated with higher prevalence and severity of angina, more
frequent evidence of myocardial ischemia, and lack of use of HR-lowering agents.
Conclusions: Despite a high rate of use of beta-blockers, stable CAD patients often have resting HR$70 bpm, which was
associated with an overall worse health status, more frequent angina and ischemia. Further HR lowering is possible in many
patients with CAD. Whether it will improve symptoms and outcomes is being tested.
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Introduction
Coronary artery disease (CAD) is the leading cause of death
worldwide [1,2], yet there is a paucity of data regarding the clinical
characteristics and management of outpatients with stable CAD.
Most of the available data are from patients admitted for acute
coronary syndromes or treated with percutaneous coronary
intervention (PCI). In addition, data often originate from Europe
or North America. The prospeCtive observational LongitudinAl
RegIstry oF patients with stable coronary arterY disease (CLAR-
IFY) registry was initiated to improve our knowledge about
patients with stable CAD from a broader geographic perspective
[3]. The main objectives of the registry are to define contemporary
stable CAD outpatients in terms of their demographic character-
istics, clinical profiles, management, and outcomes; identify gaps
between evidence-based recommendations and treatment; and
investigate long-term prognostic determinants in this population.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36284Heart rate (HR) is a primary determinant of myocardial
ischemia, and has been established as a prognostic factor in
patients with CAD [4,5,6,7,8] and in those with congestive heart
failure (CHF) [9]. It has also been correlated with the risk of future
coronary events [4,10]. Accordingly, the clinical benefits of beta-
blockers in patients with CAD are well established, particularly the
reduction in cardiovascular events in survivors of myocardial
infarction [11].
Although beta-blockers have many actions other than simply
reducing HR, emerging data show that HR reduction with pure
bradycardic agents is also associated with clinical benefits, such as
prevention of angina and reduction in myocardial ischemia
[12,13,14]; and subset analyses from the BEAUTIFUL trial
suggest that HR reduction may prevent coronary events [15,16].
Despite these data indicating the prognostic impact of HR in CAD
and the possible benefits of HR reduction, little is known regarding
HRs actually achieved in clinical practice, including in patients
receiving HR-reducing treatments such as beta-blockers. Likewise,
there is a paucity of data on the management of elevated HR in
patients with CAD in relation to the use of beta-blockers and other
HR-reducing agents.
The goal of the present analysis is to describe, using a large
contemporary database stemming from a broad geographic
representation, the HR achieved in stable outpatients with CAD
overall, and in relation to the use of beta-blockers, and to describe
the determinants of HR. An additional goal is to assess the
proportion of patients in whom resting HR exceeds some
commonly described prognostic and therapeutic thresholds.
Methods
Study Design
CLARIFY is an ongoing international, prospective, observa-
tional, longitudinal cohort study in stable CAD outpatients, with 5
years of follow-up. The study rationale and methods have been
published previously [3]. Patients were enrolled in 45 countries in
Africa, Asia, Australia, Europe, the Middle East, and North,
Central and South America. They are being treated according to
usual clinical practice at each institution, with no specific tests or
therapies defined in the study protocol.
Study Population
Patients eligible for enrolment were outpatients with stable
CAD proven by a history of at least one of the following:
documented myocardial infarction (.3 months ago); coronary
stenosis .50% on coronary angiography; chest pain with
myocardial ischemia proven by stress electrocardiogram, stress
echocardiography, or myocardial imaging; and history of coronary
artery bypass graft surgery or percutaneous coronary intervention
(performed .3 months ago).
Patients hospitalized for cardiovascular disease within the
previous 3 months (including for revascularization), patients for
whom revascularization was planned, and patients with conditions
expected to hamper participation or 5-year follow-up (e.g. limited
cooperation or legal capacity, serious non-cardiovascular disease,
conditions limiting life expectancy, or severe cardiovascular
disease [advanced heart failure, severe valve disease, history of
valve repair/replacement, etc.]) were excluded from participating
in the study.
Site Selection
In order to enroll a population of stable CAD outpatients that
mimicked the epidemiological patterns in each country, recruit-
ment was based on a predefined selection of physician types
(cardiologists, internists, primary care physicians) and aimed for
consecutive enrollment of eligible patients. Physician selection was
based on the best available sources, either local or regional,
concerning the epidemiology and medical care data, including
available market data and epidemiological surveys. A general
target of 25 patients per million inhabitants was used (range 12.5–
50) to ensure balanced representation of participating countries.
Each physician recruited 10–15 outpatients with stable CAD, as
defined by the inclusion criteria, over a brief period of time, in
order to avoid selection bias.
Baseline Evaluations and Data Management
Information collected at baseline included: demographics;
medical history; risk factors and lifestyle; results of physical
examination; HR (determined by both pulse palpation and the
results of the most recent electrocardiogram [ECG] performed
within the previous 6 months); current symptoms; laboratory
values (e.g. fasting blood glucose, hemoglobin A1c [HbA1c],
cholesterol, triglycerides, serum creatinine, and hemoglobin, if
available); and current chronic medical treatments (i.e. those taken
regularly by the patient, for $7 days before entry in the registry).
Data were collected centrally using an electronic, standardized,
international case report form (translated into local languages) and
sent electronically to the data management center where checks
for completeness, internal consistency, and accuracy were run.
Data quality control is performed onsite in 5% of sites chosen at
random in each country with, at each site, monitoring of 100% of
case report forms for source documentation and accuracy. The
study is being performed in accordance with the principles of the
Declaration of Helsinki and was approved by the National
Research Ethics Service, Isle of Wight, Portsmouth and Southeast
Hampshire Research Ethics Committee, UK. Approval was also
obtained in all 45 participating countries, in accordance with local
regulations before recruitment of the first participant. All patients
gave written informed consent to participate, in accordance with
national and local guidelines. The CLARIFY Registry is registered
in the ISRCTN registry of clinical trials with the number
ISRCTN43070564.
Statistical Analysis
All CLARIFY data are collected and analyzed at an indepen-
dent academic statistics center at the Robertson Centre for
Biostatistics, University of Glasgow, UK, which is responsible for
managing the database, performing all analyses, and storing the
data according to regulations. Baseline variables are summarized
as means, standard deviations (SDs), medians, interquartile ranges
(IQRs), and ranges for continuous data; and as counts and
percentages for categorical data.
A multivariable analysis of independent correlates of HR$70
beats per minute (bpm) was performed using a logistic regression
model. The cutoff of 70 bpm was selected based on the results of
several studies showing that it is an important prognostic threshold
across a variety of patient populations [17,18,19,20,21]. All clinical
baseline variables were considered for entry into the model as
predictors of HR$70 bpm and univariate models for each were
produced. The use of HR-lowering medications was considered to
be the most important treatment variable, and so this was the only
treatment predictor entered in the analyses. The multivariable
model was then built using a stepwise selection method applied to
the remaining significant univariate predictors, with the use of
HR-lowering medications being forced into the model.
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A total of 33,438 patients were enrolled by 2,898 investigators in
45 countries between November 2009 and July 2010. Of these, 41
patients did not meet the inclusion criteria and 112 did not provide
consent. Baseline data were available for 33,285 patients, of whom
33,177 patients had HR data recorded. Patient flow is depicted in
Figure 1; and the geographic distribution of the study population is
depicted in Figure 2.
The mean (SD) age was 64.2 (10.5) years and 77.5% of the
patients were men (Table S1). The median time since the diagnosis
of CAD was 5 years (IQR 2–9 years). Overall, 59.7% of the
patients had a history of prior myocardial infarction and 58.7%
had a history of PCI, while 23.4% had a history of coronary artery
bypass grafting (CABG). A total of 22.0% of the patients had
anginal symptoms; coronary angiography had been performed in
85.4% of the patients; and 61.9% of the patients had undergone a
non-invasive test for ischemia. The mean (SD) pulse HR was 68.3
(10.6) bpm, while the ECG-derived HR was 67.2 (11.4) bpm. HR
measured by pulse palpation was highly correlated to HR
measured by ECG (correlation 0.81; p,0.0001). The distribution
of HR as measured by pulse palpation is depicted in Figure 3.
Patients were divided in three mutually exclusive categories of
baseline pulse palpation HR: #60 bpm (9,246, 27.9%), 61–
69 bpm (9,322, 28.1%), and $70 bpm (14,609, 44.0%). The
clinical characteristics of these three HR groups are described in
Table S1. There were important, significant differences between
the HR subgroups: patients with highest HR were younger, less
frequently male or of Western descent, had less frequently
undergone PCI or CABG, but had a more frequent history of
hospitalization for CHF, stroke, history of asthma/chronic
obstructive pulmonary disease (COPD), treated hypertension,
diabetes, current smoking, and sedentarity (Table S1). They also
had more frequent and more severe anginal symptoms and CHF
symptoms (even though patients with Class IV New York Heart
Association [NYHA] were excluded), and more frequent evidence
of myocardial ischemia (Table S1).
The use of medications in the overall population and the three
HR groupings is described in Table 1. With respect to HR-
lowering medications, 75.1% of the population was treated with
beta-blockers (any molecule and any dose), 9.8% received
ivabradine, 2.5% digoxin or derivatives, 5.8% verapamil or
diltiazem, and 2.9% amiodarone or dronedarone. The median
number of HR-lowering agents used was one in the entire
population and in each of the HR subgroups. Patients with higher
HR less frequently received beta-blockers, but more frequently
received ivabradine and digoxin, than patients with lower HR
(Table 1). HR was higher as the number of HR-lowering
medications increased above 1, from 67.6 (SD 10.3) bpm for
patients receiving one agent, to 70.3 (11.8) bpm and 72.5 (12) bpm
for patients receiving 2 and 3 HR-lowering agents, respectively
(p,0.0001). The most commonly used beta-blockers were
bisoprolol (34.1% of the patients), metoprolol tartrate (15.5%),
atenolol (15.1%), metoprolol succinate (12.5%), carvedilol (11.6%),
and nebivolol (5.6%). All other molecules were used in ,2% of the
patients receiving beta-blockers.
The patient population was also divided according to the use of
beta-blockers. Baseline characteristics of patients receiving and not
receiving any dose of beta-blockers are depicted in Table S2.
Overall, 75.1% of the population received beta-blockers, but this
proportion varied largely with co-morbidities: e.g. among patients
with asthma, 50.9% were on beta-blockers. Patients receiving
beta-blockers were significantly younger, more frequently diabetic,
hypertensive, or dyslipidemic, and had a more frequent history of
myocardial infarction, PCI or CABG, hospitalization for CHF,
less frequent asthma/COPD, and more frequent anginal and CHF
symptoms (Table S2). Systolic blood pressure was similar among
patients with and without beta-blockers. The distribution of HR in
patients treated or not with beta-blockers is depicted in Figure 4.
Mean (SD) pulse HR was 67.6 (10.4) and 70.3 (11.2) bpm for
patients with and without beta-blockers, respectively. The
proportion of patients with HR$70 bpm was 41.1% and 52.9%
for patients with and without beta-blockers, respectively
(p,0.001). Among 7,301 patients with anginal symptoms, 1611
patients (22.1%) had HR#60 bpm.
A multivariable analysis was performed to identify the
independent correlates of HR (Table 2). Among the most
important predictors of elevated HR$70 bpm were Asian
ethnicity, asthma/COPD, diabetes, lack of use of HR-lowering
drugs, increased diastolic blood pressure, angina class, hospital-
ization for CHF, and evidence of myocardial ischemia. Converse-
ly, increasing physical activity was associated with decreased risk of
elevated HR$70 bpm.
Discussion
This analysis provides a description of HR among stable
outpatients with CAD. In this population, the mean (SD) pulse
HR was 68.3 (10.6) bpm. Despite the fact that three quarters of the
CAD population received treatment with beta-blockers, nearly
half of the population had HR$70 bpm, an emerging prognostic
threshold in CAD patients with angina [6,8,15,16,21], and only
27.9% of all patients with CAD had HR#60 bpm. Even among
patients on beta-blockers, the proportion with HR$70 bpm was
41.1%. Also, among patients with anginal symptoms, only 22.1%
achieved a HR#60 bpm, despite the fact that stable angina
guidelines recommend a target HR of 55–60 bpm in patients with
angina on beta-blockers [22]. This is consistent with observations
from the EuroHeart Survey on angina [23], in which 19% of
patients had HR#62 bpm. By multivariable analysis, there were
many independent predictors of HR$70 bpm, a large proportion
of which are markers of a poor health status, such as higher blood
pressure, presence of diabetes, dyslipidemia, increased alcohol
intake, history of chronic heart failure, increased body mass and
lack of physical exercise. Among other independent predictors of
Figure 1. Patient flow chart.
doi:10.1371/journal.pone.0036284.g001
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were also important and strong correlates of elevated HR, as was
the lack of use of HR-lowering agents.
These findings have important clinical implications: HR
remains elevated in a substantial proportion of patients. Elevated
HR has been associated with worse clinical outcomes in prior
studies [4,5,6,7,8,10]; and in the present study, was independently
associated with more frequent evidence of myocardial ischemia
and a worse anginal status. Elevated HR was, as expected, also
more frequent among patients who did not receive HR-lowering
agents. Thus, further HR reduction can be achieved and may
yield substantial clinical benefit in these patients. Indeed, HR
lowering with beta-blockers has been shown to have potent anti-
ischemic and anti-anginal effects in patients with CAD [24] and
yields improved clinical outcomes after myocardial infarction [11],
but the effects of beta-blockers on HR are difficult to separate from
their other major pharmacodynamic properties. Extrapolating
from the evidence of prognostic benefit of beta-blockers in patients
with angina who have a history of prior myocardial infarction
(most of which antedate the advent of modern reperfusion therapy)
or heart failure, both European and American guidelines for the
management of stable angina suggest that beta-blockers be the
first-line antianginal therapy in patients without contraindications
[24,25]. Yet, in the present analysis, poorly controlled HR was
independently associated with diabetes mellitus, more severe
angina class, higher blood pressure, evidence of myocardial
ischemia, and physical inactivity, factors that point to patient
populations most likely to benefit from beta-blockers. Because low
blood pressure may be a limiting factor for using beta-blockers, it is
noteworthy that patients not on beta-blockers did not actually
have lower blood pressure. In fact, there was an association
between increasing HR and higher mean systolic and diastolic
blood pressures, which suggests that in this cohort, low blood
pressure was not a major barrier to using beta-blockers and
achieving HR control. In contradistinction to heart failure [26],
there is no recommended target dose or beta-blocker molecule
recommended in treating angina, and thus a wide variety of agents
and doses are commonly used. Titration is usually based on resting
HR achieved and therefore it is conceivable that increasing beta-
blocker dosage might achieve superior HR control.
There are multiple potential barriers to more widespread use of
beta-blockers at appropriate doses to achieve adequate HR
Figure 2. Geographical distribution of patients with baseline HR on palpation (n=33,177).
doi:10.1371/journal.pone.0036284.g002
Figure 3. HR distribution in stable CAD patients.
doi:10.1371/journal.pone.0036284.g003
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goals by clinicians [27], access to care and reimbursement, co-
morbidities that represent contraindications or decrease tolerance
to beta-blockers, side effects of beta-blockers, and marketing efforts
for other agents. Interestingly, in the present cohort, the
proportion of patients fully reimbursed for drugs was actually
greater among patients not receiving than among patients
receiving beta-blockers, suggesting that lack of full reimbursement
is not a major barrier to the prescription of beta-blockers.
Likewise, it is striking that two thirds of patients not receiving beta-
blockers had no apparent symptoms or conditions that would
potentially contraindicate their use. Therefore, it is likely that it is
possible to improve HR control by increasing the use of beta-
blockers (and possibly their dose).
Whether other antianginal agents that lower HR might provide
similar benefits as those of beta-blockers (i.e. beyond symptom
control) is still debated. The rates of cardiac death and myocardial
infarction are not different when comparing beta-blockers and
calcium antagonists [28]. Pure HR-reducing agents such as
ivabradine have been shown to be potent anti-anginal agents,
alone and in combination with beta-blockers [12,14]. In the
BEAUTIFUL randomized trial in patients with stable CAD and
left ventricular dysfunction [15], ivabradine did not improve
Table 1. Medications of the study population classified according to resting HR by palpation.
Population According to Palpation HR
Variable
Patients
with Data
Total Population
(n=33,177)
#60 bpm
(n=9,246)
61–69 bpm
(n=9,322)
$70 bpm
(n=14,609) p-Value
Aspirin, n (%) 33,157 29,068 (87.7) 8,071 (87.3) 8,257 (88.6) 12,740 (87.3) 0.0037
Thienopyridine, n (%) 33,111 8,959 (27.1) 2,561 (27.8) 2,493 (26.8) 3,905 (26.8) 0.21
Other antiplatelets, n (%) 33,108 3,069 (9.3) 742 (8.0) 875 (9.4) 1,452 (10.0) ,0.0001
Oral anticoagulants, n (%) 33,134 2,738 (8.3) 673 (7.3) 685 (7.4) 1,380 (9.5) ,0.0001
Beta-blockers, n (%) 33,161 24,910 (75.1) 7,390 (80.0) 7,281 (78.1) 10,239 (70.1) ,0.0001
Symptoms indicative of intolerance or
contraindication to beta-blockers, n (%)
33,149 4,783 (14.4) 1,451 (15.7) 1,202 (12.9) 2,130 (14.6) ,0.0001
Ivabradine, n (%) 33,160 3,259 (9.8) 677 (7.3) 757 (8.1) 1,825 (12.5) ,0.0001
Calcium antagonists, n (%) 33,155 9,038 (27.3) 2,344 (25.4) 2,525 (27.1) 4,169 (28.6) ,0.0001
Verapamil or diltiazem, n (%) 33,155 1,931 (5.8) 421 (4.6) 491 (5.3) 1,019 (7.0) ,0.0001
ACE inhibitors, n (%) 33,160 17,044 (51.4) 4,792 (51.8) 4,835 (51.9) 7,417 (50.8) 0.15
Angiotensin II receptor blockers, n (%) 33,156 8,800 (26.5) 2,354 (25.5) 2,430 (26.1) 4,016 (27.5) 0.0012
Lipid-lowering drugs, n (%) 33,163 30,606 (92.3) 8,710 (94.2) 8,634 (92.7) 13,262 (90.8) ,0.0001
Long-acting nitrates, n (%) 33,156 7,329 (22.1) 1,761 (19.1) 1,999 (21.5) 3,569 (24.5) ,0.0001
Other antianginal agents, n (%) 33,151 4,618 (13.9) 999 (10.8) 1,284 (13.8) 2,335 (16.0) ,0.0001
Diuretics, n (%) 33,156 9,695 (29.2) 2,478 (26.8) 2,600 (27.9) 4,617 (31.6) ,0.0001
Other antihypertensive agents, n (%) 33,156 2,277 (6.9) 602 (6.5) 604 (6.5) 1,071 (7.3) 0.011
Digoxin and derivatives, n (%) 33,158 837 (2.5) 149 (1.6) 169 (1.8) 519 (3.6) ,0.0001
Amiodarone/dronedarone, n (%) 33,151 966 (2.9) 344 (3.7) 234 (2.5) 388 (2.7) ,0.0001
Other antiarrhythmics, n (%) 33,151 305 (0.9) 99 (1.1) 78 (0.8) 128 (0.9) 0.20
Antidiabetic agents, n (%) 33,160 8,153 (24.6) 1,698 (18.4) 2,186 (23.5) 4,269 (29.2) ,0.0001
Thyroid HRT, n (%) 33,157 1,422 (4.3) 427 (4.6) 393 (4.2) 602 (4.1) 0.17
Number of antianginals, median (IQR) 33,177 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) ,0.0001
Number of HR-lowering agents, median
(IQR)
33,177 1 (1–1) 1 (1–1) 1 (1–1) 1 (1–1) 0.0119
Number of antianginals or HR-lowering
agents, median (IQR)
33,177 1 (1–2) 1 (1–2) 1 (1–2) 1 (1–2) ,0.0001
ACE, angiotensin-converting enzyme; HR, heart rate; HRT, hormone replacement therapy; IQR, interquartile range.
doi:10.1371/journal.pone.0036284.t001
Figure 4. Distribution of HR for patients with versus without
beta-blocker use. The vertical lines represent the minimum and
maximum values. The box represents the lower (25
th percentile) and
upper (75
th percentile) quartiles. Within the box, the vertical line is the
median and the diamond the mean. Values.1.5 times the interquartile
range were considered outliers and are shown as individual circles.
doi:10.1371/journal.pone.0036284.g004
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the incidence of coronary outcomes in the subset of patients with
HR$70 bpm [8]. These effects were more marked in a post-hoc
analysis of patients with limiting anginal symptoms at baseline
[16]. Whether pure HR reduction improves clinical outcomes in
patients with CAD and without heart failure is currently being
explored in the ongoing SIGNIFY randomized trial (http://www.
controlled-trials.com/ISRCTN61576291). Also, because in-
creased heart rate was correlated to an overall poor health status
and lifestyle (e.g. with less physical activity, increased alcohol
intake and higher prevalence of risk factors), lifestyle changes and
Table 2. Factors associated with HR$70 bpm.
Variable OR (95% CI) Pr.Chi-Square
Female sex 1.21 (1.14–1.28) ,0.0001
Age (per 10-year increase) 0.89 (0.87–0.92) ,0.0001
Ethnicity ,0.0001
Japanese/Korean 1.63 (1.41–1.88)
South Asian 1.92 (1.76–2.11)
Chinese 1.51 (1.38–1.67)
Hispanic 1.43 (1.28–1.59)
Black/African 0.88 (0.71–1.10)
Unknown 0.80 (0.74–0.87)
Angina CCS Class 0.018
I 1.07 (0.97–1.18)
II 1.10 (1.02–1.19)
III 1.18 (1.04–1.34)
IV 0.97 (0.61–1.54)
Asthma/COPD 1.63 (1.50–1.78) ,0.0001
Atrial fibrillation/flutter 1.35 (1.23–1.48) ,0.0001
BMI (per 2-unit increase) 1.03 (1.02–1.04) ,0.0001
Current smoker 1.37 (1.27–1.47) ,0.0001
Diabetes 1.54 (1.47–1.63) ,0.0001
Dyslipidemia 0.93 (0.88–0.98) 0.0101
Family history of premature CAD 0.94 (0.90–0.99) 0.026
Diastolic blood pressure (per 10-mmHg increase) 1.31 (1.28–1.34) ,0.0001
Current evidence of myocardial ischemia 1.19 (1.11–1.27) ,0.0001
Prior hospitalization for CHF 1.19 (1.06–1.32) 0.0023
Coronary artery bypass graft 0.93 (0.87–0.99) 0.025
Percutaneous coronary intervention 0.89 (0.84–0.95) 0.0001
Alcohol intake (units/week) 0.0005
.40 1.02 (0.69–1.51)
20–40 1.10 (0.97–1.26)
.0a n d,20 0.91 (0.87–0.96)
Physical activity level ,0.0001
Light physical activity most weeks 0.88 (0.82–0.94)
$20 min vigorous physical activity 1–2 times a week 0.75 (0.69–0.81)
$20 min vigorous activity $3 times a week 0.64 (0.59–0.70)
Non-invasive test performed 0.80 (0.76–0.85) ,0.0001
Coronary territories with stenosis .50%; coronary angiography not done1.13 (1.04–1.22) 0.0036
Coronary territories with stenosis .50%; right coronary artery 0.94 (0.89–0.99) 0.014
Not taking HR-lowering drugs 1.52 (1.42–1.61) ,0.0001
Reimbursement of cardiovascular agents 0.026
None 1.02 (0.96–1.09) –
Full 0.94 (0.89–0.995) –
BMI, body mass index; CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; CHF, congestive heart failure; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; HR, heart rate; OR, odds.
doi:10.1371/journal.pone.0036284.t002
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the risk associated with increased heart rate.
The CLARIFY registry also provides a useful description of
clinical characteristics, demographics, risk factors, drug treatment,
and management of patients with CAD in stable outpatients from
a broad geographic perspective. It provides a useful reference,
which differs from the highly selected patient populations often
enrolled in randomized trials [29,30], and stems from a more
diverse geographic representation, as trials are often skewed
towards predominant representation of Europe and North
America, and with diverse ethnicity.
Finally, while HR is emerging as a potentially important
prognostic determinant in patients with CAD [4,5,6,7,8,10] and
heart failure [9], the determinants of HR are not well known. The
present study allowed a detailed univariate and multivariable
analysis of the correlates of elevated HR, which highlighted
important and previously unrecognized factors in determining HR
in this population. Apart from the previously mentioned greater
burden of risk factors and markers of a poorer health status, such
as increased alcohol intake, increased body mass index and lower
level of physical activity, the presence of asthma/COPD, for
instance, was one of the strongest predictors of an elevated HR
($70 bpm) (odds ratio 1.63; 95% confidence interval 1.50–1.78,
p,0.0001), which is consistent with the fact that use of beta-
blockers is far less frequent in this population, who may in fact
often receive beta agonists. In CLARIFY, 75.1% of the overall
population received beta-blocker therapy (regardless of the dose)
whereas this proportion was only 50.9% among patients with
asthma/COPD. Likewise, increasing physical activity was associ-
ated with decreasing risks of elevated HR, a finding consistent with
the well-documented effects of regular exercise on lowering HR
[31].
While the CLARIFY registry is a large, international initiative
taking place in 45 countries in four continents, it is subject to
limitations. The study population may not fully reflect regional
differences in clinical characteristics and patterns of care of stable
CAD patients, and results may not therefore be representative of
practice elsewhere. For example, no patients from the United
States participated in CLARIFY. In addition, despite attempts to
optimize the representativeness of the registry, it was not
population-based. Finally, pending the availability of outcomes,
the cross-sectional nature of the analysis limits the ability to draw
causal inferences from the observations made which are suscep-
tible to confounding.
In conclusion, despite the use of beta-blockers in three quarters
of patients, nearly half of stable outpatients with CAD had a
resting HR$70 bpm. Even among patients on beta-blockers, 41%
had HR$70 bpm. An increasing HR was an independent
correlate, among many other factors suggestive of an overall
poorer health status, of higher prevalence and severity of angina,
and higher prevalence of myocardial ischemia. These findings
suggest that further HR lowering is possible in patients with stable
CAD. Whether it will impact symptoms, ischemia, and risk of
cardiovascular events is being tested.
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